The nation of Zimbabwe has turned down a substantial American healthcare agreement worth $367m (272 million pounds) over five years due to the United States' insistence on sensitive biological samples.
This move came to light after a official document from December was disclosed, which showed President Emmerson Mnangagwa deemed the agreement was "unbalanced".
A government spokesman has since clarified that the US was demanding access to genetic material for scientific study and commercial gain while was unwilling to share the resulting advantages from future treatments.
"We are forced to start the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had donated over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for further negotiations to reach a deal acceptable to all parties so the nation's critical HIV treatment initiative can proceed.
Broader Background
Zimbabwe's decision comes after a similar case in neighbouring Kenya, where a high court halted a similar health funding agreement following legal challenges were raised about the safety of Kenyans' medical information.
Since returning to office last year, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had overseen aid for the US government, but Trump argued its expenditure was "wasteful" and his administration was pursuing government-to-government agreements to enhance transparency and responsibility.
As per statements, Sixteen African countries have so far agreed to similar agreements, constituting more than $18.3bn in new funding.
Specifics of the Declined Deal
The money for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation could have provided significant benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on antiretroviral therapy through American-funded initiatives," Tremont added.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to share its biological resources and data for a long time, without any corresponding guarantee of access to any scientific breakthroughs – like new medicines or tests – that might be developed from that provided information," he stated.
"Effectively, our country would provide the basic resources for medical research without any assurance that the resulting innovations would be available to our population should a future disease outbreak arise."
National Interest and International Frameworks
Mangwana further noted that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were upending frameworks previously established via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to deal with potential pandemics.
"This mechanism is intended to guarantee that when a nation provides its information, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to create them."
These objections over the US deal "are not meant as anti-American sentiment," he added.
"We encourage continued discussions with our US partners on how subsequent collaboration could be structured in a way that honours the independence and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the government's concerns, but recommended that talks must proceed given that a large portion of the nation's Aids initiatives depended on international support.
"In cases where technical issues exist, including those relating to data governance or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," it commented.
This impasse underscores the ongoing challenges between accepting vital international aid and safeguarding a country's data in an increasingly interconnected world.